Natco Pharma faces legal setback for Imbruvica generic in US

Natco Pharma Limited said that a US District Court has given a decision in favor of Pharmacyclics, a subsidiary of AbbVie, the brand owner of Imbruvica (ibrutinib) in a PIV litigation that involved the cancer drug.

The Indian pharma company said that it will review the judgment and assess all options for appealing the judgment, alongside Alvogen Pine Brook, its marketing partner in the US for the product.

Natco Pharma said that it has a strong case and will continue to vigorously defend it.

Natco Pharma faces legal setback for Imbruvica generic in US. Image courtesy of 3D Animation Production Company from Pixabay.

In 2018, the Hyderabad-based firm and Alvogen Pine Brook had filed an abbreviated new drug application (ANDA) with PIV certification for the generic equivalent of Imbruvica.